当前位置：
X-MOL 学术
›
Eur. J. Heart Fail.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial
European Journal of Heart Failure ( IF 18.2 ) Pub Date : 2024-03-07 , DOI: 10.1002/ejhf.3179 Justin Ezekowitz 1 , Wendimagegn Alemayehu 1 , Frank Edelmann 2 , Piotr Ponikowski 3 , Carolyn S.P. Lam 4 , Christopher M. O'Connor 5 , Javed Butler 6, 7 , Stefano Corda 8 , Ciaran J. McMullan 9 , Cynthia M. Westerhout 1 , Adriaan A. Voors 10 , Robert J. Mentz 11 , Paul W. Armstrong 1 ,
European Journal of Heart Failure ( IF 18.2 ) Pub Date : 2024-03-07 , DOI: 10.1002/ejhf.3179 Justin Ezekowitz 1 , Wendimagegn Alemayehu 1 , Frank Edelmann 2 , Piotr Ponikowski 3 , Carolyn S.P. Lam 4 , Christopher M. O'Connor 5 , Javed Butler 6, 7 , Stefano Corda 8 , Ciaran J. McMullan 9 , Cynthia M. Westerhout 1 , Adriaan A. Voors 10 , Robert J. Mentz 11 , Paul W. Armstrong 1 ,
Affiliation
|
In VICTORIA, vericiguat compared with placebo reduced the risk of cardiovascular death (CVD) and heart failure hospitalization (HFH) in patients enrolled after a worsening heart failure (WHF) event. We examined clinical outcomes and efficacy of vericiguat as it relates to background use of loop diuretics in patients with WHF.
中文翻译：
射血分数降低的心力衰竭患者的利尿剂使用和结果：VICTORIA 试验的见解
在维多利亚州，与安慰剂相比，维利西呱降低了心力衰竭（WHF）事件恶化后入组患者的心血管死亡（CVD）和心力衰竭住院（HFH）风险。我们检查了 Vericiguat 的临床结果和疗效，因为它与 WHF 患者使用袢利尿剂的背景有关。
更新日期：2024-03-08
中文翻译：
射血分数降低的心力衰竭患者的利尿剂使用和结果：VICTORIA 试验的见解
在维多利亚州，与安慰剂相比，维利西呱降低了心力衰竭（WHF）事件恶化后入组患者的心血管死亡（CVD）和心力衰竭住院（HFH）风险。我们检查了 Vericiguat 的临床结果和疗效，因为它与 WHF 患者使用袢利尿剂的背景有关。
京公网安备 11010802027423号